A 52-week update of a multicentre Italian real-world experience on effectiveness and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis

J Eur Acad Dermatol Venereol. 2023 Mar;37(3):e384-e388. doi: 10.1111/jdv.18648. Epub 2022 Oct 18.
No abstract available

Publication types

  • Multicenter Study
  • Letter

MeSH terms

  • Adolescent
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Dermatitis, Atopic* / drug therapy
  • Double-Blind Method
  • Humans
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • dupilumab
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Monoclonal